MicroRNA in vitro diagnostics using immunoassay analyzers
BACKGROUND: The implementation of new biomarkers into clinical practice is one of the most important areas in medical research. Besides their clinical impact, novel in vitro diagnostic markers promise to have a substantial effect on healthcare costs. Although numerous publications report the discove...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 2015
|
| In: |
Clinical chemistry
Year: 2015, Volume: 61, Issue: 4, Pages: 600-607 |
| ISSN: | 1530-8561 |
| DOI: | 10.1373/clinchem.2014.232165 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1373/clinchem.2014.232165 Verlag, kostenfrei, Volltext: http://clinchem.aaccjnls.org/content/61/4/600 
|
| Author Notes: | Andreas Kappel, Christina Backes, Yiwei Huang, Sachli Zafari, Petra Leidinger, Benjamin Meder, Herbert Schwarz, Walter Gumbrecht, Eckart Meese, Cord F. Staehler, and Andreas Keller |
| Summary: | BACKGROUND: The implementation of new biomarkers into clinical practice is one of the most important areas in medical research. Besides their clinical impact, novel in vitro diagnostic markers promise to have a substantial effect on healthcare costs. Although numerous publications report the discovery of biomarkers, only a fraction of those markers are routinely used. One key challenge is a measurement system that is compatible with clinical workflows. METHODS: We designed a new immunoassay for microRNA (miRNA) quantification. The assay combines streptavidin-linked microparticles, a biotinylated catcher oligonucleotide complementary to a single miRNA species, and finally, a monoclonal antibody to DNA/RNA heterohybrids labeled with acridinium ester. Importantly, our assay runs on standard immunoassay analyzers. After a technical validation of the assay, we evaluated the clinical performance on 4 Alzheimer disease miRNAs. RESULTS: Our assay has an analytical specificity of 99.4% and is at the same time sensitive (concentrations in the range of 1 pmol/L miRNA can be reliably profiled). Because the novel approach did not require amplification steps, we obtained high reproducibility for up to 40 biological replicates. Importantly, our assay prototype exhibited a time to result of <3 h. With human blood samples, the assay was able to measure 4 miRNAs that can detect Alzheimer disease with a diagnostic accuracy of 82% and showed a Pearson correlation >0.994 with the gold standard qRT-PCR. CONCLUSIONS: Our miRNA immunoassay allowed the measurement of miRNA signatures with sufficient analytical sensitivity and high specificity on commonly available laboratory equipment. |
|---|---|
| Item Description: | Gesehen am 14.07.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1530-8561 |
| DOI: | 10.1373/clinchem.2014.232165 |